ArticlePacing and clinical electrophysiology : PACE2026
Real-World Treatment of Patients With Sinus Node Dysfunction and Heart Failure With Preserved Ejection Fraction.
Article in Pacing and clinical electrophysiology : PACE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPermanent pacemaker (PPM) implantation is recommended in patients with sinus node dysfunction (SND). In patients with coexisting heart failure with preserved ejection fraction (HFpEF), clinicians may be hesitant to treat SND due to concerns about exacerbating heart failure. Little is known about real-world PPM utilization and disease burden in the HFpEF population that has been assumed to benefit from low heart rates. This study aims to characterize the disease burden and PPM utilization in patients with SND+HFpEF versus SND-only in a Medicare population.
methodsPatients diagnosed with SND were identified in the Medicare administrative claims database and stratified by presence or abscence of prior evidence of HFpEF. Rates of the following clinical outcomes were compared between the cohorts during follow-up: PPM implant, HF hospitalization, atrial fibrillation (AF) hospitalization, second/third-degree AV block or HFrEF, myocardial infarction (MI), ischemic stroke, and all-cause mortality.
resultsSND+HFpEF (N = 26,986) patients were older (81.1 vs. 78.5, p < 0.0001) and more likely to be female (63.5% vs. 49.9%, p < 0.0001) than SND-only patients (N = 74,269). Median follow-up time was 884 days (IQR 476-1408). The PPM implant rate during follow-up was lower in the SND+HFpEF population (HR = 0.811, p < 0.0001). The SND+HFpEF population had higher HF and AF hospitalizations (HR = 2.229 and HR = 1.174, both p < 0.0001), and higher incidence of second/third-degree AV block and HFrEF (HR = 1.364 and HR = 1.640, both p < 0.0001) than the SND-only population.
conclusionsPPM implant rates were lower, and overall disease burden was greater in HFpEF+SND patients compared to SND-only patients. Future work should focus on optimizing treatment pathways for patients with HFpEF and SND.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.